Peptide questions · Ipamorelin

Ipamorelin side effects: what studies and users report

Reviewed Evidence: ModeratePublished by PepVault

The side effects most commonly reported for ipamorelin are headache, flushing and nausea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.

Its safety note opens: ipamorelin is a selective ghrelin-receptor / GH-secretagogue pentapeptide; published pharmacology emphasizes its selectivity — unlike GHRP-2/GHRP-6 it did not raise ACTH or cortisol in animal studies (none of the three changed FSH, LH, prolactin or TSH there); human data cover GH only.

What is commonly reported with ipamorelin

  • Headache
  • Flushing
  • Nausea
  • Water retention
  • Numbness/tingling

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other growth hormone compounds the library lists it for
EffectAlso listed for (of 13)
Headache4: CJC-1295 with DAC, CJC-1295 no DAC, Sermorelin, GHRP-2
Flushing3: CJC-1295 with DAC, CJC-1295 no DAC, Sermorelin
Nausea2: Sermorelin, Tesamorelin
Water retention9: CJC-1295 with DAC, CJC-1295 no DAC, Sermorelin, GHRP-2 and 5 more
Numbness/tinglingNone: listed for Ipamorelin alone
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track ipamorelin in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which ipamorelin side effects the growth hormone group shares

Across the 14 growth hormone compounds in the library, the effects listed most often are water retention (10 of 14), headache (5 of 14), injection site reaction (5 of 14) and fatigue (4 of 14). Ipamorelin shares 4 of its 5 listed effects with at least one other growth hormone compound; numbness/tingling is listed for ipamorelin alone.

What the ipamorelin safety notes say

The library’s safety note

Ipamorelin is a selective ghrelin-receptor / GH-secretagogue pentapeptide; published pharmacology emphasizes its selectivity — unlike GHRP-2/GHRP-6 it did not raise ACTH or cortisol in animal studies (none of the three changed FSH, LH, prolactin or TSH there); human data cover GH only. FDA lists ipamorelin acetate in compounding category 2, citing a possible risk of immune reactions and a published report of serious adverse events, including a death, when it was given intravenously for gut motility. Reported/observed effects relate to GH/IGF-1 elevation: transient water retention, headache, flushing, and — because GH affects insulin sensitivity — possible glucose changes, plus carpal-tunnel-like symptoms or joint discomfort with sustained GH exposure. Human data remain limited and long-term safety is not established; most effects are described as reversible on cessation. Discuss glucose-relevant monitoring with your clinician.

The library’s interaction note

No formal human drug-interaction studies exist. The main mechanism-based consideration is glucose: because GH can reduce insulin sensitivity, combining with insulin or antidiabetic agents is worth clinician-guided glucose monitoring. It is classically stacked with a GHRH analog (CJC-1295) for amplified GH release — no combination-specific human interaction data exists. No documented interaction with SSRIs, anticoagulants, or thyroid medication; raise all medications with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the ipamorelin reports come from

The library rates the evidence on ipamorelin as moderate: animal studies plus some human data.

Of the library’s 7 research notes on ipamorelin, 2 rest on clinical data and 5 on community reports.

Our 10 study pages on ipamorelin: 1 animal study (ferrets), 1 randomized trial, 6 animal studies (rats), 1 animal study (rats, swine and dogs) and 1 animal study (rats and swine).

So ipamorelin has controlled trials in people to set its listed effects against.

What our ipamorelin study pages report on safety

Ipamorelin reduced cisplatin weight loss by about 24% in ferrets

Animal study, ferrets, 2024: In ferrets, neither ipamorelin nor anamorelin given by belly injection changed vomiting in the first day (acute phase) or the later days (delayed phase). Only anamorelin was tested by injection into the brain, where it cut acute vomiting by 60%.

Ipamorelin did not speed first meal after bowel surgery vs placebo

Randomized trial, human, 2014: The median time from first dose to tolerating a standard solid meal was 25.3 h with ipamorelin and 32.6 h with placebo, a gap that was not statistically significant (p = 0.15). Adverse events that began during treatment showed up in 87.5% of the ipamorelin group and 94.8% of the placebo group.

Questions people ask

What are the side effects of ipamorelin?

The side effects most commonly reported for ipamorelin are headache, flushing and nausea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.

Do ipamorelin’s side effects come from human studies?

The library rates the evidence on ipamorelin as moderate, and the library’s evidence on it includes controlled trials in people.

Which ipamorelin side effects are its own?

Among the growth hormone compounds, the library lists numbness/tingling for ipamorelin alone.

Does ipamorelin interact with other medicines?

The library’s interaction note on ipamorelin begins: No formal human drug-interaction studies exist.

More on ipamorelin

Track it in the app

PepVault for iPhone

Track ipamorelin in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo